BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Clinical Trials Initiated For A New Molecule Jointly Identified By IRIC And Bristol-Myers Squibb Company (BMY)


2/26/2014 9:35:18 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

February 26, 2014 -- Université de Montréal (UdeM) is proud to announce the start of clinical trials of a new molecule acting on a novel therapeutic target. This molecule was identified by the Institute of Research in Immunology and Cancer (IRIC) and Bristol-Myers Squibb (NYSE: BMY) working in close collaboration.

“The preclinical data on this molecule is very encouraging, and we eagerly await the clinical results,” says Anne Marinier, Principal Investigator and Medicinal Chemistry Director at IRIC.

This new molecule was identified by a joint research team that included medicinal chemists, biologists, and other scientists from both IRIC and Bristol-Myers Squibb with funding from Bristol-Myers Squibb and support from UdeM and the Institute of Research on Immunology and Cancer-Commercialization of Research (IRICoR) (please see press release dated September 18, 2013).

“We are delighted to begin this crucial phase of the project, the most advanced discovery to date to emerge from our partnership agreements with Bristol-Myers Squibb. The start of these clinical trials marks an important step in our collaboration and triggers a milestone payment from Bristol-Myers Squibb, which we will invest in new research programs. In addition, the identification of this molecule represents a major achievement by our 30 medicinal chemists and biologists who are currently working on several projects in partnership with global pharmaceutical companies,” explains Michel Bouvier, President and Chief Executive Officer of IRICoR, and Principal Investigator at IRIC.

About the Institute for Research in Immunology and Cancer

An ultra-modern research hub and training centre located in the heart of the Université de Montreal, the Institute for Research in Immunology and Cancer (IRIC) was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer. For more information: www.iric.ca

About the Institute for Research in Immunology and Cancer – Commercialization of Research

IRICoR is a not-for-profit organization whose mandate is to accelerate the discovery, development and commercialization of novel drugs that originate at Université de Montreal’s Institute for Research in Immunology and Cancer and related research units. IRICoR, as a Centre of Excellence in Commercialization and Research, invests in highly innovative projects to rapidly transition them from academia to the market, while identifying the best development partners for these commercially promising projects. For more information: www.iricor.ca

About Université de Montréal

Deeply rooted in Montreal and dedicated to its international mission, the Université de Montréal is one of the top universities in the French-speaking world. Founded in 1878, the Université de Montréal today has 15 faculties and together with its two affiliated schools, HEC Montréal and École Polytechnique, constitutes the largest centre of higher education and research in Québec and one of the major centres in North America. It brings together 2,500 professors and researchers, accommodates more than 60,000 students. For more information: www.udm.ca

Information
Steven J. Klein, Ph. D., MBA
Vice-President, Business Development
Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR)
514 343-6647¦steven.klein@iricor.ca

Gilles Noël, Ph. D.
Directeur, Recherche et valorisation
Université de Montréal (UdeM)
514 343-2307¦gilles.noel@umontreal.ca

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES